

## DAFTAR PUSTAKA

- Aplenc, R., Alonzo, T.A., Gerbing, R.B., Smith, F.O., Meshinchi, S., Ross, J.A., *et al.*, 2006. Ethnicity and survival in childhood acute myeloid leukemia: A report from the Children's Oncology Group. *Blood*, 108(1): 74–80.
- Arber, D.A., Orazi, A., Hasserjian, R.P., Borowitz, M.J., Calvo, K.R., Kvasnicka, H.M., *et al.*, 2022. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. *Blood*, 140(11): 1200–1228.
- Aung, M.M.K., Mills, M.L., Bittencourt-Silvestre, J., Keeshan, K. 2021. Insights into the molecular profiles of adult and paediatric acute myeloid leukaemia. *Mol Oncol*, 15(9): 2253–2272.
- Bansal, D., Davidson, A., Supriyadi, E., Njuguna, F., Ribeiro, R.C., Kaspers, G.J.L. 2019. SIOP PODC adapted risk stratification and treatment guidelines: Recommendations for acute myeloid leukemia in resource-limited settings. *Pediatr Blood Cancer*, (October): 1–12.
- Binder, S., Luciano, M., Horejs-Hoeck, J. 2018. The cytokine network in acute myeloid leukemia (AML): A focus on pro- and anti-inflammatory mediators. *Cytokine Growth Factor Rev*, 43: 8–15.
- Bochennek, K., Hassler, A., Perner, C., Gilfert, J., Schöning, S., Klingebiel, T., *et al.*, 2016. Infectious complications in children with acute myeloid leukemia: Decreased mortality in multicenter trial AML-BFM 2004. *Blood Cancer J*, 6(1): 8–11.
- Bolouri, H., Ries, R.E., Wiedeman, A.E., Hylkema, T., Scheiding, S., Gersuk, V.H., *et al.*, 2022. Inflammatory bone marrow signaling in pediatric acute myeloid leukemia distinguishes patients with poor outcomes. *Nat Commun*, 13(1): 1–12.
- Bowen, R.C., Little, N.A.B., Harmer, J.R., Ma, J., Mirabelli, L.G., Roller, K.D., *et al.*, 2017. Neutrophil-to-lymphocyte ratio as prognostic indicator in gastrointestinal cancers: a systematic review and meta-analysis. *Oncotarget*, 8(19): 32171–32189.
- Buonacera, A., Stancanelli, B., Colaci, M., Malatino, L. 2022. Neutrophil to Lymphocyte Ratio: An Emerging Marker of the Relationships between the Immune System and Diseases. *Int J Mol Sci*, 23(7).
- Chen, X., Pan, J., Wang, S., Hong, Shandie, Hong, Shunrong, He, S. 2019. The epidemiological trend of acute myeloid leukemia in childhood: A population-based analysis. *J Cancer*, 10(20): 4824–4835.

- Corces-Zimmerman, M.R., Hong, W.J., Weissman, I.L., Medeiros, B.C., Majeti, R. 2014. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. *Proc Natl Acad Sci U S A*, 111(7): 2548–2553.
- Creutzig, U., Van Den Heuvel-Eibrink, M.M., Gibson, B., Dworzak, M.N., Adachi, S., De Bont, E., *et al.*, 2012. Diagnosis and management of acute myeloid leukemia in children and adolescents: Recommendations from an international expert panel. *Blood*, 120(16): 3167–3205.
- Creutzig, U., Kutny, M.A., Barr, R., Schlenk, R.F., Ribeiro, R.C. 2018. Acute myelogenous leukemia in adolescents and young adults. *Pediatr Blood Cancer*, 65(9).
- Domnicu, A.E., Boia, E.R., Mogoi, M., Manea, A.-M., Marcovici, T.M., Mărginean, O., *et al.*, 2023. The Neutrophil-to-Lymphocyte Ratio (NLR) Can Predict Sepsis's Presence and Severity in Malnourished Infants—A Single Center Experience. *Children*, 10(10): 1616.
- Duarte, D., Hawkins, E.D., Akinduro, O., Ang, H., De Filippo, K., Kong, I.Y., *et al.*, 2018. Inhibition of Endosteal Vascular Niche Remodeling Rescues Hematopoietic Stem Cell Loss in AML. *Cell Stem Cell*, 22(1): 64-77.e6.
- Flores-Lujano, J., Duarte-Rodríguez, D.A., Jiménez-Hernández, E., Martín-Trejo, J.A., Allende-López, A., Peñaloza-González, J.G., *et al.*, 2022. Persistently high incidence rates of childhood acute leukemias from 2010 to 2017 in Mexico City: A population study from the MIGICCL. *Front Public Heal*, 10.
- Forget, P., Khalifa, C., Defour, J.-P., Latinne, D., Van Pel, M.-C., De Kock, M. 2017. What is the normal value of the neutrophil-to-lymphocyte ratio? *BMC Res Notes*, 10(1): 12.
- Gaidzik, V.I., Bullinger, L., Schlenk, R.F., Zimmermann, A.S., Röck, J., Paschka, P., *et al.*, 2011. RUNX1 Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group. *J Clin Oncol*, 29(10): 1364–1372.
- Gal Etzioni, T.R., Fainshtain, N., Nitzan-Luques, A., Goldstein, G., Weinreb, S., Temper, V., *et al.*, 2024. Invasive Fungal Infections in Children with Acute Leukemia: Epidemiology, Risk Factors, and Outcome. *Microorganisms*, 12(1): 1–12.
- Galati, P.C., Ribeiro, C.M., Pereira, L.T.G., Amato, A.A. 2022. The association between excess body weight at diagnosis and pediatric leukemia prognosis: A systematic review and meta-analysis. *Blood Rev*, 51: 100870.
- van Galen, P., Hovestadt, V., Wadsworth II, M.H., Hughes, T.K., Griffin, G.K., Battaglia, S., *et al.*, 2019. Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity. *Cell*, 176(6): 1265-1281.e24.

- Geissal, E.D., Coffey, T., Gilbert, D.N. 2010. Clinical Importance of the Failure to Detect Immature Neutrophils by an Automated Hematology Analyzer. *Infect Dis Clin Pract*, 18(6): 374–378.
- Ghafoor, T., Ahmed, S., Khalil, S., Farah, T. 2020. Impact of malnutrition on treatment outcome of paediatric acute myeloid leukemia. *J Coll Physicians Surg Pakistan*, 30(10): 1021–1025.
- Ghafoor, T., Khalil, S., Farah, T., Ahmed, S., Sharif, I. 2020. Prognostic Factors in Childhood Acute Myeloid Leukemia; Experience from A Developing Country. *Cancer Rep*, 3(5): 1–9.
- Goel, P., Kuznetsova, V., Franceski, A., Luca, F., Costa, A., Crown, B., *et al.*, 2023. Leukemic Environment Alters Neutrophils Worsening Disease Progression. *J Immunol*, 210(1\_Supplement): 84.07-84.07.
- Green, C.L., Koo, K.K., Hills, R.K., Burnett, A.K., Linch, D.C., Gale, R.E. 2010. Prognostic Significance of CEBPA Mutations in a Large Cohort of Younger Adult Patients With Acute Myeloid Leukemia: Impact of Double CEBPA Mutations and the Interaction With FLT3 and NPM1 Mutations. *J Clin Oncol*, 28(16): 2739–2747.
- Guthrie, G.J.K., Charles, K.A., Roxburgh, C.S.D., Horgan, P.G., McMillan, D.C., Clarke, S.J. 2013. The systemic inflammation-based neutrophil–lymphocyte ratio: Experience in patients with cancer. *Crit Rev Oncol Hematol*, 88(1): 218–230.
- Han, B.K., Wysham, K.D., Cain, K.C., Tyden, H., Bengtsson, A.A., Lood, C. 2020. Neutrophil and lymphocyte counts are associated with different immunopathological mechanisms in systemic lupus erythematosus. *Lupus Sci Med*, 7(1): e000382.
- Hemmati, S., Haque, T., Gritsman, K. 2017. Inflammatory signaling pathways in preleukemic and leukemic stem cells. *Front Oncol*, 7(NOV).
- Hong, S.P., Woo, J.B., Kim, H.Y. 2025. Use of the Neutrophil-to-Lymphocyte Ratio Improves the Accuracy of Outcome Prediction in Patients with Acute Traumatic Subdural Hematoma Undergoing Surgical Treatment. *World Neurosurg*, 195: 123642.
- Hossain, M.J., Xie, L. 2015. Sex disparity in childhood and young adult acute myeloid leukemia (AML) survival: Evidence from US population data. *Cancer Epidemiol*, 39(6): 892–900.
- Hossain, M.J., Xie, L., Caywood, E.H. 2015. Prognostic factors of childhood and adolescent acute myeloid leukemia (AML) survival: Evidence from four decades of US population data. *Cancer Epidemiol*, 39(5): 720–726.
- Hotchkiss, R.S., Monneret, G., Payen, D. 2013. Immunosuppression in sepsis: a

novel understanding of the disorder and a new therapeutic approach. *Lancet Infect Dis*, 13(3): 260–268.

Howard, R., Kanetsky, P.A., Egan, K.M. 2019. Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer. *Sci Rep*, 9(1): 1–10.

Inaba, H., Fan, Y., Pounds, S., Geiger, T.L., Rubnitz, J.E., Ribeiro, R.C., *et al.*, 2008. Clinical and biologic features and treatment outcome of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis. *Cancer*, 113(3): 522–529.

Inaba, H., Surprise, H.C., Pounds, S., Cao, X., Howard, S.C., Ringwald-Smith, K., *et al.*, 2012. Effect of body mass index on the outcome of children with acute myeloid leukemia. *Cancer*, 118(23): 5989–5996.

Iwasaki, H., Akashi, K. 2007. Hematopoietic developmental pathways: on cellular basis. *Oncogene*, 26(47): 6687–6696.

Jaime-Pérez, J.C., Padilla-Medina, J.R., Fernández, L.T., Herrera-Garza, J.L., Gutiérrez-Aguirre, C.H., Tarín-Arzaga, L., *et al.*, 2018. Outcomes of Adolescents and Young Adults With Acute Myeloid Leukemia Treated in a Single Latin American Center. *Clin Lymphoma, Myeloma Leuk*, 18(4): 286–292.

Jain, H., Rengaraj, K., Sharma, V., Bonda, A., Chanana, R., Thorat, J., *et al.*, 2020. Infection Prevalence in Adolescents and Adults With Acute Myeloid Leukemia Treated in an Indian Tertiary Care Center. *JCO Glob Oncol*, (6): 1684–1695.

Jan, M., Majeti, R. 2013. Clonal evolution of acute leukemia genomes. *Oncogene*, 32(2): 135–140.

Jiao, X., Zhou, J., Liang, X., Zhu, J., Xiao, M., Ding, Y., *et al.*, 2025. Dynamic monitoring of lymphocyte subsets at different disease stages can predict the prognosis of acute myeloid leukemia especially in complete remission status. *Sci Rep*, 15(1): 1–15.

Karalexi, M.A., Markozannes, G., Tagkas, C.F., Katsimpris, A., Tseretopoulou, X., Tsilidis, K.K., *et al.*, 2022. Nutritional Status at Diagnosis as Predictor of Survival from Childhood Cancer: A Review of the Literature. *Diagnostics*, 12(10): 1–13.

Kaya, T., Açıkgöz, S.B., Yıldırım, M., Nalbant, A., Altaş, A.E., Cinemre, H. 2019. Association between neutrophil-to-lymphocyte ratio and nutritional status in geriatric patients. *J Clin Lab Anal*, 33(1).

Khoury, J.D., Solary, E., Abla, O., Akkari, Y., Alaggio, R., Apperley, J.F., *et al.*, 2022. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.

*Leukemia*, 36(7): 1703–1719.

- Kittivisuit, S., Jongthitnon, N., Sripornsawan, P., Songthawee, N., Chavananon, S., Limratchapong, C., *et al.*, 2023. Hyperleukocytosis in Childhood Acute Leukemia: Early Complications and Survival Outcomes. *Cancers (Basel)*, 15(12): 3072.
- Klein, K., de Haas, V., Kaspers, G.J.L. 2018. Clinical challenges in de novo pediatric acute myeloid leukemia. *Expert Rev Anticancer Ther*, 18(3): 277–293.
- Laumont, C.M., Banville, A.C., Gilardi, M., Hollern, D.P., Nelson, B.H. 2022. Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities. *Nat Rev Cancer*, 22(7): 414–430.
- Luyang, H., Zeng, F., Lei, Y., He, Q., Zhou, Y., Xu, J. 2025. Bidirectional role of neutrophils in tumor development. *Mol Cancer*, 24(1): 22.
- Mamo, W., Moges, A., Yesuf, S.A., Mohamedsaid, A., Arega, G. 2024. Treatment outcomes of pediatrics acute myeloid leukemia (AML) and associated factors in the country's tertiary referral hospital, Ethiopia. *BMC Cancer*, 24(1): 1–9.
- Mercan, R., Bitik, B., Tufan, A., Bozbulut, U.B., Atas, N., Ozturk, M.A., *et al.*, 2016. The Association Between Neutrophil/Lymphocyte Ratio and Disease Activity in Rheumatoid Arthritis and Ankylosing Spondylitis. *J Clin Lab Anal*, 30(5): 597–601.
- Miraki-Moud, F., Anjos-Afonso, F., Hodby, K.A., Griessinger, E., Rosignoli, G., Lillington, D., *et al.*, 2013. Acute myeloid leukemia does not deplete normal hematopoietic stem cells but induces cytopenias by impeding their differentiation. *Proc Natl Acad Sci U S A*, 110(33): 13576–13581.
- Moosmann, J., Krusemark, A., Dittrich, S., Ammer, T., Rauh, M., Woelfle, J., *et al.*, 2022. Age- and sex-specific pediatric reference intervals for neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, and platelet-to-lymphocyte ratio. *Int J Lab Hematol*, 44(2): 296–301.
- Mushtaq, M.U., Chaudhary, S.G., Guru Murthy, G.S., Hall, A.C., Atallah, E.L., Mattison, R.J. 2018. Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Relapsed/Refractory Acute Myeloid Leukemia. *Blood*, 132: 5246–5246.
- Nacaroglu, H.T., İsgüder, R., Bent, S., Erdem Bahceci, S., Ceylan, G., Korkmaz, H.A., *et al.*, 2016. Can neutrophil/lymphocyte ratio be a novel biomarker of inflammation in children with asthma? *Eur J Inflamm*, 14(2): 109–112.
- Naess, A., Nilssen, S.S., Mo, R., Eide, G.E., Sjursen, H. 2017. Role of neutrophil to lymphocyte and monocyte to lymphocyte ratios in the diagnosis of bacterial infection in patients with fever. *Infection*, 45(3): 299–307.

- Naji, N.S., Sathish, M., Karantanos, T. 2024. Inflammation and Related Signaling Pathways in Acute Myeloid Leukemia. *Cancers (Basel)*, 16(23): 1–19.
- Nielsen, L.H., Kristensen, D.T., Jakobsen, L.H., Bøgsted, M., Gregersen, H., Madsen, J., *et al.*, 2024. Socioeconomic Status and Overall Survival Among Patients With Hematological Malignant Neoplasms. *JAMA Netw Open*, 7(3): e241112.
- Nurmalasari, S.A., Widjajanto, P.H., Mulatish, S., Purwanto, I. 2012. Leukemia Myeloblastik Akut: Luaran Terapi di RSUP DR. Sardjito, Yogyakarta, 2004-2008. *Indones J Cancer*, 6(2).
- Van Oorschot, V., Beckers, M. 2022. Neutrophil To Lymphocyte Ratio As a Prognostic Factor in Aml and Mds. *HemaSphere*, 6: 1673–1674.
- Pandian, J., Raghavan, V., Manuprasad, A., Shenoy, P.K., Nair, C.K. 2020. Infection at diagnosis—a unique challenge in acute myeloid leukemia treatment in developing world. *Support Care Cancer*, 28(11): 5449–5454.
- Peng, S., Bao, Y. 2022. A narrative review of immune checkpoint mechanisms and current immune checkpoint therapy. *Ann Blood*, 7(1): 1–15.
- Perzoli, A., Koedijk, J.B., Zwaan, C.M., Heidenreich, O. 2024. Targeting the innate immune system in pediatric and adult AML. *Leukemia*, 38(6): 1191–1201.
- Pietras, E.M. 2017. Inflammation: A key regulator of hematopoietic stem cell fate in health and disease. *Blood*, 130(15): 1693–1698.
- Pievani, A., Biondi, M., Tomasoni, C., Biondi, A., Serafini, M. 2020. Location first: Targeting acute myeloid leukemia within its niche. *J Clin Med*, 9(5).
- Porcu, P., Cripe, L.D., Ng, E.W., Bhatia, S., Danielson, C.M., Orazi, A., *et al.*, 2000. Hyperleukocytic Leukemias and Leukostasis: A Review of Pathophysiology, Clinical Presentation and Management. *Leuk Lymphoma*, 39(1–2): 1–18.
- Poynter, J.N., Richardson, M., Roesler, M., Blair, C.K., Hirsch, B., Nguyen, P., *et al.*, 2017. Chemical exposures and risk of acute myeloid leukemia and myelodysplastic syndromes in a population-based study. *Int J Cancer*, 140(1): 23–33.
- Proctor, M.J., Morrison, D.S., Talwar, D., Balmer, S.M., Fletcher, C.D., O'Reilly, D.S.J., *et al.*, 2011. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. *Eur J Cancer*, 47(17): 2633–2641.
- Puumala, S.E., Ross, J.A., Aplenc, R., Spector, L.G. 2013. Epidemiology of childhood acute myeloid leukemia. *Pediatr Blood Cancer*, 60(5): 728–733.

- Quessada, J., Cucchini, W., Saultier, P., Loosveld, M., Harrison, C.J., Lafage-Pochitaloff, M. 2021. Cytogenetics of pediatric acute myeloid leukemia: A review of the current knowledge. *Genes*, 12 (6): 1-32.
- Rangel, F.A.L., Valencia, V.C., Guijosa, M.Á.G., Penagos, C.C. 2017. Acute Myeloid Leukemia — Genetic Alterations and Their Clinical Prognosis. *Int J Hematol Stem Cell Res*, 11(4): 328–339.
- Rasche, M., Zimmermann, M., Borschel, L., Bourquin, J.P., Dworzak, M., Klingebiel, T., *et al.*, 2018. Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012. *Leukemia*, 32(10): 2167–2177.
- Razzouk, B.I., Estey, E., Pounds, S., Lensing, S., Pierce, S., Brandt, M., *et al.*, 2006. Impact of age on outcome of pediatric acute myeloid leukemia: A report from 2 institutions. *Cancer*, 106(11): 2495–2502.
- Reinhardt, D., Antoniou, E., Waack, K. 2022. Pediatric Acute Myeloid Leukemia— Past, Present, and Future. *J Clin Med*, 11(3): 504.
- Resztak, J.A., Choe, J., Nirmalan, S., Wei, J., Bruinsma, J., Houpt, R., *et al.*, 2023. Analysis of transcriptional changes in the immune system associated with pubertal development in a longitudinal cohort of children with asthma. *Nat Commun*, 14(1): 230.
- de Rooij, J.D.E., Michel Zwaan, C., van den Heuvel-Eibrink, M. 2015. Pediatric AML: From biology to clinical management. *J Clin Med*, 4(1): 127–149.
- Rubnitz, J.E., Inaba, H., Dahl, G., Ribeiro, R.C., Bowman, W.P., Taub, J., *et al.*, 2010. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. *Lancet Oncol*, 11(6): 543–552.
- Sala, A., Rossi, E., Antillon, F., Molina, A.L., de Maselli, T., Bonilla, M., *et al.*, 2012. Nutritional status at diagnosis is related to clinical outcomes in children and adolescents with cancer: A perspective from Central America. *Eur J Cancer*, 48(2): 243–252.
- Schietinger, A., Greenberg, P.D. 2014. Tolerance and exhaustion: defining mechanisms of T cell dysfunction. *Trends Immunol*, 35(2): 51–60.
- Senjo, H., Onozawa, M., Hidaka, D., Yokoyama, S., Yamamoto, S., Tsutsumi, Y., *et al.*, 2022. High CRP-albumin ratio predicts poor prognosis in transplant ineligible elderly patients with newly diagnosed acute myeloid leukemia. *Sci Rep*, 12(1): 8885. <https://www.nature.com/articles/s41598-022-12813-1>.
- Shlush, L.I., Mitchell, A., Heisler, L., Abelson, S., Ng, S.W.K., Trotman-Grant, A., *et al.*, 2017. Tracing the origins of relapse in acute myeloid leukaemia to stem cells. *Nature*, 547(7661): 104–108.

- Simon, A.K., Hollander, G.A., McMichael, A. 2015. Evolution of the immune system in humans from infancy to old age. *Proc R Soc B Biol Sci*, 282(1821): 20143085.
- Sjakti, H.A., Gatot, D., Wahidiat, P.A., Kosasih, A., Setianingsih, I. 2021. Role of cytogenetic profiles as prognostic factors for complete remission after induction phase in acute myeloblastic leukemia. *Paediatr Indones Indones*, 61(6): 343–349.
- Stefaniuk, P., Muzyka-Kasietczuk, J., Koczkodaj, D., Hus, M., Podhorecka, M. 2025. Reading Between the Lines: Complete Blood Count-Derived Parameters as Prognostic Factors in Patients With Newly Diagnosed Acute Myeloid Leukemia. *Clin Med Insights Oncol*, 19(Mcv).
- Stefaniuk, P., Szymczyk, A., Podhorecka, M. 2020. The neutrophil to lymphocyte and lymphocyte to monocyte ratios as new prognostic factors in hematological malignancies – a narrative review. *Cancer Manag Res*, 12: 2961–2977.
- Supriyadi, E., Purwanto, I., Widjajanto, P.H. 2013. Terapi Leukemia Mieloblastik Akut Anak: Protokol Ara-C, Doxorubicine dan Etoposide [ADE] vs Modifikasi Nordic Society of Pediatric Hematology and Oncology (m-NOPHO). *Sari Pediatr*, 14(6): 345.
- Supriyadi, E., Widjajanto, P.H., Purwanto, I., Cloos, J., Veerman, A.J.P., Sutaryo, S. 2011. Incidence of childhood leukemia in Yogyakarta, Indonesia, 1998-2009. *Pediatr Blood Cancer*, 57(4): 588–593.
- Tabe, Y., Konopleva, M. 2017. Leukemia Stem Cells Microenvironment. In *Advances in Experimental Medicine and Biology*. 19–32.
- Tang, T., Huang, X., Zhang, G., Hong, Z., Bai, X., Liang, T. 2021. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. *Signal Transduct Target Ther*, 6(1).
- Taufiq, M. 2024. Neutrophil-to-Lymphocyte Ratio is Significantly Increased in Central Obesity. *J Heal Technol Sci*, 5(1): 57–61.
- Tekin, R., Aktar, F., Yılmaz, K., Tekin, S., Ayaz, C. 2020. Comparison of Inflammatory Markers between Adult and Pediatric Brucellosis Patients. *Rev Soc Bras Med Trop*, 53.
- Templeton, A.J., McNamara, M.G., Šeruga, B., Vera-Badillo, F.E., Aneja, P., Ocaña, A., *et al.*, 2014. Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. *JNCI J Natl Cancer Inst*, 106(6).
- Tomizawa, D., Tsujimoto, S.I. 2023. Risk-Stratified Therapy for Pediatric Acute Myeloid Leukemia. *Cancers (Basel)*, 15(16): 1–21.

- Vilchis-Ordoñez, A., Ramírez-Ramírez, D., Pelayo, R. 2021. The triad inflammation-microenvironment-tumor initiating cells in leukemia progression. *Curr Opin Physiol*, 19: 211–218.
- Wang, X., Qiu, L., Li, Z., Wang, X.Y., Yi, H. 2018. Understanding the multifaceted role of neutrophils in cancer and autoimmune diseases. *Front Immunol*, 9: 1–10.
- Wang, Y., Huang, J., Rong, L., Wu, P., Kang, M., Zhang, X., *et al.*, 2016. Impact of age on the survival of pediatric leukemia: An analysis of 15083 children in the SEER database. *Oncotarget*, 7(50): 83767–83774.
- Webb, D.K.H., Harrison, G., Stevens, R.F., Gibson, B.G., Hann, I.M., Wheatley, K. 2001. Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia. *Blood*, 98(6): 1714–1720.
- Van Weelderen, R.E., Klein, K., Natawidjaja, M.D., De Vries, R., Kaspers, G.J.L. 2021. Outcome of pediatric acute myeloid leukemia (AML) in low- and middle-income countries: a systematic review of the literature. *Expert Rev Anticancer Ther*, 21(7): 765–780.
- Withycombe, J.S., Smith, L.M., Meza, J.L., Merkle, C., Faulkner, M.S., Ritter, L., *et al.*, 2015. Weight change during childhood acute lymphoblastic leukemia induction therapy predicts obesity: A report from the Children’s Oncology Group. *Pediatr Blood Cancer*, 62(3): 434–439.
- Yan., W., Qiyi., Z., Chen., P., Lin., S., Xue-Feng., L., Dong-Min., K. 2011. Neutrophils promote motility of cancer cells via a hyaluronan-mediated TLR4/PI3K activation loop. *J Pathol*, 225(3): 438–447.
- Yoon, J.H., Kwak, W.S., Ahn, Y.S. 2018. A brief review of relationship between occupational benzene exposure and hematopoietic cancer. *Ann Occup Environ Med*, 30(1): 5–9.
- Zahorec, R. 2021. Neutrophil-to-lymphocyte ratio, past, present and future perspectives. *Bratislava Med J*, 122(07): 474–488.
- Zajac-Spychała, O., Skalska-Sadowska, J., Wachowiak, J., Szmydki-Baran, A., Hutnik, Ł., Matysiak, M., *et al.*, 2019. Infections in children with acute myeloid leukemia: increased mortality in relapsed/refractory patients. *Leuk Lymphoma*, 60(12): 3028–3035.
- Zhang, Q., Yang, Q., Weng, Y., Huang, Z., Chen, R., Zhu, Y., *et al.*, 2021. Neutrophil-to-lymphocyte ratio correlates with prognosis and response to chemotherapy in patients with non-M3 de novo acute myeloid leukemia. *Transl Cancer Res*, 10(2): 1013–1024.